vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and CPI Card Group Inc. (PMTS). Click either name above to swap in a different company.
CPI Card Group Inc. is the larger business by last-quarter revenue ($153.1M vs $139.2M, roughly 1.1× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 4.8%, a 30.7% gap on every dollar of revenue. On growth, CPI Card Group Inc. posted the faster year-over-year revenue change (22.3% vs 18.4%). CPI Card Group Inc. produced more free cash flow last quarter ($35.2M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 16.9%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
CPI Card Group Inc. is a leading provider of payment card production and associated solutions, including contactless and contact credit/debit cards, prepaid cards, and card personalization services. It primarily serves financial institutions, fintech firms, and retail brands across its core North American market.
ADMA vs PMTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $153.1M |
| Net Profit | $49.4M | $7.3M |
| Gross Margin | 63.8% | 31.5% |
| Operating Margin | 45.1% | 12.0% |
| Net Margin | 35.5% | 4.8% |
| Revenue YoY | 18.4% | 22.3% |
| Net Profit YoY | -55.9% | 8.5% |
| EPS (diluted) | $0.20 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $153.1M | ||
| Q3 25 | $134.2M | $138.0M | ||
| Q2 25 | $122.0M | $129.8M | ||
| Q1 25 | $114.8M | $122.8M | ||
| Q4 24 | $117.5M | $125.1M | ||
| Q3 24 | $119.8M | $124.8M | ||
| Q2 24 | $107.2M | $118.8M | ||
| Q1 24 | $81.9M | $111.9M |
| Q4 25 | $49.4M | $7.3M | ||
| Q3 25 | $36.4M | $2.3M | ||
| Q2 25 | $34.2M | $518.0K | ||
| Q1 25 | $26.9M | $4.8M | ||
| Q4 24 | $111.9M | $6.8M | ||
| Q3 24 | $35.9M | $1.3M | ||
| Q2 24 | $32.1M | $6.0M | ||
| Q1 24 | $17.8M | $5.5M |
| Q4 25 | 63.8% | 31.5% | ||
| Q3 25 | 56.3% | 29.7% | ||
| Q2 25 | 55.1% | 30.9% | ||
| Q1 25 | 53.2% | 33.2% | ||
| Q4 24 | 53.9% | 34.1% | ||
| Q3 24 | 49.8% | 35.8% | ||
| Q2 24 | 53.6% | 35.7% | ||
| Q1 24 | 47.8% | 37.1% |
| Q4 25 | 45.1% | 12.0% | ||
| Q3 25 | 38.0% | 9.4% | ||
| Q2 25 | 35.1% | 7.3% | ||
| Q1 25 | 30.4% | 11.5% | ||
| Q4 24 | 32.6% | 12.7% | ||
| Q3 24 | 33.1% | 14.3% | ||
| Q2 24 | 36.6% | 12.5% | ||
| Q1 24 | 26.7% | 12.6% |
| Q4 25 | 35.5% | 4.8% | ||
| Q3 25 | 27.1% | 1.7% | ||
| Q2 25 | 28.1% | 0.4% | ||
| Q1 25 | 23.4% | 3.9% | ||
| Q4 24 | 95.2% | 5.4% | ||
| Q3 24 | 30.0% | 1.0% | ||
| Q2 24 | 29.9% | 5.1% | ||
| Q1 24 | 21.7% | 4.9% |
| Q4 25 | $0.20 | $0.62 | ||
| Q3 25 | $0.15 | $0.19 | ||
| Q2 25 | $0.14 | $0.04 | ||
| Q1 25 | $0.11 | $0.40 | ||
| Q4 24 | $0.45 | $0.56 | ||
| Q3 24 | $0.15 | $0.11 | ||
| Q2 24 | $0.13 | $0.51 | ||
| Q1 24 | $0.08 | $0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $21.7M |
| Total DebtLower is stronger | $72.1M | $286.7M |
| Stockholders' EquityBook value | $477.3M | $-17.3M |
| Total Assets | $624.2M | $403.2M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $21.7M | ||
| Q3 25 | $61.4M | $16.0M | ||
| Q2 25 | $90.3M | $17.1M | ||
| Q1 25 | $71.6M | $31.5M | ||
| Q4 24 | $103.1M | $33.5M | ||
| Q3 24 | $86.7M | $14.7M | ||
| Q2 24 | $88.2M | $7.5M | ||
| Q1 24 | $45.3M | $17.1M |
| Q4 25 | $72.1M | $286.7M | ||
| Q3 25 | $72.4M | $308.4M | ||
| Q2 25 | — | $310.9M | ||
| Q1 25 | — | $280.7M | ||
| Q4 24 | $72.3M | $280.4M | ||
| Q3 24 | — | $280.2M | ||
| Q2 24 | — | $269.7M | ||
| Q1 24 | — | $265.3M |
| Q4 25 | $477.3M | $-17.3M | ||
| Q3 25 | $431.2M | $-25.7M | ||
| Q2 25 | $398.3M | $-29.0M | ||
| Q1 25 | $373.4M | $-29.7M | ||
| Q4 24 | $349.0M | $-35.6M | ||
| Q3 24 | $231.9M | $-42.8M | ||
| Q2 24 | $188.3M | $-44.6M | ||
| Q1 24 | $153.7M | $-48.5M |
| Q4 25 | $624.2M | $403.2M | ||
| Q3 25 | $568.7M | $407.1M | ||
| Q2 25 | $558.4M | $399.8M | ||
| Q1 25 | $510.6M | $351.9M | ||
| Q4 24 | $488.7M | $349.7M | ||
| Q3 24 | $390.6M | $342.3M | ||
| Q2 24 | $376.4M | $321.4M | ||
| Q1 24 | $350.9M | $319.8M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $39.6M |
| Free Cash FlowOCF − Capex | $34.6M | $35.2M |
| FCF MarginFCF / Revenue | 24.8% | 23.0% |
| Capex IntensityCapex / Revenue | 0.8% | 2.9% |
| Cash ConversionOCF / Net Profit | 0.72× | 5.39× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $41.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $39.6M | ||
| Q3 25 | $13.3M | $10.0M | ||
| Q2 25 | $21.1M | $4.3M | ||
| Q1 25 | $-19.7M | $5.6M | ||
| Q4 24 | $50.2M | $26.7M | ||
| Q3 24 | $25.0M | $12.5M | ||
| Q2 24 | $45.6M | $-4.8M | ||
| Q1 24 | $-2.2M | $8.9M |
| Q4 25 | $34.6M | $35.2M | ||
| Q3 25 | $-1.1M | $5.3M | ||
| Q2 25 | $18.7M | $533.0K | ||
| Q1 25 | $-24.4M | $292.0K | ||
| Q4 24 | $47.5M | $21.6M | ||
| Q3 24 | $24.0M | $11.1M | ||
| Q2 24 | $43.6M | $-6.0M | ||
| Q1 24 | $-4.6M | $7.4M |
| Q4 25 | 24.8% | 23.0% | ||
| Q3 25 | -0.8% | 3.8% | ||
| Q2 25 | 15.3% | 0.4% | ||
| Q1 25 | -21.2% | 0.2% | ||
| Q4 24 | 40.4% | 17.3% | ||
| Q3 24 | 20.0% | 8.9% | ||
| Q2 24 | 40.7% | -5.0% | ||
| Q1 24 | -5.6% | 6.6% |
| Q4 25 | 0.8% | 2.9% | ||
| Q3 25 | 10.7% | 3.4% | ||
| Q2 25 | 2.0% | 2.9% | ||
| Q1 25 | 4.1% | 4.3% | ||
| Q4 24 | 2.3% | 4.0% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 1.9% | 1.0% | ||
| Q1 24 | 2.9% | 1.3% |
| Q4 25 | 0.72× | 5.39× | ||
| Q3 25 | 0.36× | 4.32× | ||
| Q2 25 | 0.62× | 8.39× | ||
| Q1 25 | -0.73× | 1.17× | ||
| Q4 24 | 0.45× | 3.94× | ||
| Q3 24 | 0.70× | 9.70× | ||
| Q2 24 | 1.42× | -0.79× | ||
| Q1 24 | -0.12× | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PMTS
| US Debit And Credit | $128.9M | 84% |
| US Prepaid Debit | $24.4M | 16% |
